Article

FDA Panel Votes to Expand Use of Pneumococcal Vaccine to Adults

An FDA advisory committee has voted 14-1 in favor of expanding the indication for the pneumococcal 13-valent conjugate vaccine (Prevnar 13) to include use in adults 50 and older.

Currently the vaccine is approved only for use in children.

The FDA's Vaccines and Related Biologics Advisory Committee voted for accelerated approval, reserved for biologics or drugs that are intended to treat serious or life-threatening illnesses and that provide a meaningful benefit over existing treatments.

Read the full story at: http://www.medpagetoday.com/InfectiousDisease/Vaccines/29755

Source: MedPage Today

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Hadar Avihai Lev-Tov, MD
4 experts in this video
4 experts in this video
Ayodeji Adegunsoye, MD, PhD, MSc
David J. Maron, MD, FASPC, Stanford University School of Medicine
Hadar Avihai Lev-Tov, MD
Senator Vincent Polistina (R, New Jersey)
Karen Vo talks about antibullying campaigns and pediatric patients with derm conditions
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo